File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Advanced stage and unfavorable Hodgkin's disease in the Chinese - A 20- year experience

TitleAdvanced stage and unfavorable Hodgkin's disease in the Chinese - A 20- year experience
Authors
Issue Date1999
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/35105
Citation
American Journal Of Hematology, 1999, v. 61 n. 3, p. 159-163 How to Cite?
AbstractWe retrospectively analyzed 57 patients with advanced stage (stage III/IV) or unfavorable (presence of B symptoms or bulky disease) Hodgkin's disease from January 1977 to December 1997. There were 29 male and 28 female patients. The median age was 27 years old (range, 13-59). Lactate dehydrogenase levels ranged from 104 units/l to 2320 units/l (median, 433). Eighteen (31.6%), 13 (22.8%), and 26 (45.6%) patients had stage II bulky, stage III, and stage IV disease, respectively. Twenty-five (44%) patients had B symptoms. One (1.8%), 3 (5.3%), 36 (63.2%), and 17 (29.8%) had lymphocyte predominant, lymphocyte depleted, nodular sclerosis, and mixed cellularity histology, respectively. Chemotherapy regimens included mechlorethamine, vincristine, procarbazine, prednisone (MOPP) (n = 9), adriamycin, bleomycin, vinblastine, dacarbazine (ABVD) (n = 23), MOPP alternating with ABVD (n = 13), and COPP-ABV hybrid (n = 12). Complete remission was achieved in 47 (82.4%) patients. Eleven patients (23%) relapsed after the first complete remission and four (36%) attained a second complete remission with salvage chemotherapy. Projected overall survival was 69.0% at 10 years and 20 years. Disease-free survival rates were 71% at 10 years and 20 years. Of the potential prognostic factors analyzed (age, sex, stage, lactate dehydrogenase, serum albumin level, regimen, B symptoms and bulky disease) by using the Cox regression model, only a low albumin level was found to adversely affect overall survival (P = 0.003). In conclusion, despite the relative low incidence of Hodgkin's disease in Hong Kong Chinese, the treatment outcomes in patients with advanced stage or unfavorable Hodgkin's disease is comparable to Caucasian patients.
Persistent Identifierhttp://hdl.handle.net/10722/162328
ISSN
2015 Impact Factor: 5.0
2015 SCImago Journal Rankings: 1.761
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChim, CSen_US
dc.contributor.authorKwong, YLen_US
dc.contributor.authorLie, AKWen_US
dc.contributor.authorLee, CKen_US
dc.contributor.authorHo, FCSen_US
dc.contributor.authorLiang, Ren_US
dc.date.accessioned2012-09-05T05:19:03Z-
dc.date.available2012-09-05T05:19:03Z-
dc.date.issued1999en_US
dc.identifier.citationAmerican Journal Of Hematology, 1999, v. 61 n. 3, p. 159-163en_US
dc.identifier.issn0361-8609en_US
dc.identifier.urihttp://hdl.handle.net/10722/162328-
dc.description.abstractWe retrospectively analyzed 57 patients with advanced stage (stage III/IV) or unfavorable (presence of B symptoms or bulky disease) Hodgkin's disease from January 1977 to December 1997. There were 29 male and 28 female patients. The median age was 27 years old (range, 13-59). Lactate dehydrogenase levels ranged from 104 units/l to 2320 units/l (median, 433). Eighteen (31.6%), 13 (22.8%), and 26 (45.6%) patients had stage II bulky, stage III, and stage IV disease, respectively. Twenty-five (44%) patients had B symptoms. One (1.8%), 3 (5.3%), 36 (63.2%), and 17 (29.8%) had lymphocyte predominant, lymphocyte depleted, nodular sclerosis, and mixed cellularity histology, respectively. Chemotherapy regimens included mechlorethamine, vincristine, procarbazine, prednisone (MOPP) (n = 9), adriamycin, bleomycin, vinblastine, dacarbazine (ABVD) (n = 23), MOPP alternating with ABVD (n = 13), and COPP-ABV hybrid (n = 12). Complete remission was achieved in 47 (82.4%) patients. Eleven patients (23%) relapsed after the first complete remission and four (36%) attained a second complete remission with salvage chemotherapy. Projected overall survival was 69.0% at 10 years and 20 years. Disease-free survival rates were 71% at 10 years and 20 years. Of the potential prognostic factors analyzed (age, sex, stage, lactate dehydrogenase, serum albumin level, regimen, B symptoms and bulky disease) by using the Cox regression model, only a low albumin level was found to adversely affect overall survival (P = 0.003). In conclusion, despite the relative low incidence of Hodgkin's disease in Hong Kong Chinese, the treatment outcomes in patients with advanced stage or unfavorable Hodgkin's disease is comparable to Caucasian patients.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/35105en_US
dc.relation.ispartofAmerican Journal of Hematologyen_US
dc.rightsAmerican Journal of Hematology. Copyright © John Wiley & Sons, Inc.-
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Therapeutic Useen_US
dc.subject.meshBleomycin - Administration & Dosageen_US
dc.subject.meshCyclophosphamide - Administration & Dosageen_US
dc.subject.meshDacarbazine - Administration & Dosageen_US
dc.subject.meshDisease-Free Survivalen_US
dc.subject.meshDoxorubicin - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHodgkin Disease - Drug Therapy - Mortality - Pathologyen_US
dc.subject.meshHong Kongen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMechlorethamine - Administration & Dosageen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Stagingen_US
dc.subject.meshPrednisone - Administration & Dosageen_US
dc.subject.meshProcarbazine - Administration & Dosageen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshSurvival Analysisen_US
dc.subject.meshTime Factorsen_US
dc.subject.meshVinblastine - Administration & Dosageen_US
dc.subject.meshVincristine - Administration & Dosageen_US
dc.titleAdvanced stage and unfavorable Hodgkin's disease in the Chinese - A 20- year experienceen_US
dc.typeArticleen_US
dc.identifier.emailChim, CS:jcschim@hku.hken_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityChim, CS=rp00408en_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/(SICI)1096-8652(199907)61:3<159::AID-AJH1>3.0.CO;2-Gen_US
dc.identifier.pmid10398307-
dc.identifier.scopuseid_2-s2.0-0032992612en_US
dc.identifier.hkuros49581-
dc.identifier.hkuros49421-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032992612&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume61en_US
dc.identifier.issue3en_US
dc.identifier.spage159en_US
dc.identifier.epage163en_US
dc.identifier.isiWOS:000081161500001-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridChim, CS=7004597253en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US
dc.identifier.scopusauthoridLie, AKW=24284842400en_US
dc.identifier.scopusauthoridLee, CK=36882460200en_US
dc.identifier.scopusauthoridHo, FCS=7103408147en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats